Malaria resurgence after significant reduction by mass drug administration on Ngodhe Island, Kenya

Scientific Reports

Volumn 9, Issue 1, 2019, Pages

  Kagaya, Wataru ^a   Gitaka, Jesse ^b   Chan, Chim W ^a,c,d   Kongere, James ^e   Md Idris, Zulkarnain ^c,f   Deng, Changsheng ^g   Kaneko, Akira ^a,c,e  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MOUNT KENYA UNIVERSITY   (Kenya)

^c KAROLINSKA INSTITUTE   (Sweden)

^d BINGHAMTON UNIVERSITY   (United States)

^e NAGASAKI UNIVERSITY   (Japan)

^f UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^g GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; HEMOGLOBIN; PRIMAQUINE;

ADVERSE EVENT; ANEMIA; ANIMAL; COMPLICATION; DRUG EFFECT; GEOGRAPHY; HUMAN; ISLAND (GEOLOGICAL); KENYA; MALARIA; MASS DRUG ADMINISTRATION; MEDICATION COMPLIANCE; METABOLISM; PARASITE; PARASITOLOGY; PREVALENCE; RECURRENT DISEASE; RISK FACTOR;

ANEMIA; ANIMALS; ANTIMALARIALS; GEOGRAPHY; HEMOGLOBINS; HUMANS; ISLANDS; KENYA; MALARIA; MASS DRUG ADMINISTRATION; MEDICATION ADHERENCE; PARASITES; PREVALENCE; PRIMAQUINE; RECURRENCE; RISK FACTORS;

EID: 85076519603     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-019-55437-8     Document Type: Article

References (56)

1. World Health Organization: World Malaria Report 2018 (WHO, Geneva, Switzerland) (2018).
2. World Health Organization: A Framework for Malaria Elimination (WHO, Geneva, Switzerland) (2015).
3. Okell, L. C. et al. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat. Commun. 3, 1237, 10.1038/ncomms2241 (2012).
4. Ouédraogo, A. L. et al. Dynamics of the human infectious reservoir for malaria determined by mosquito feeding assays and ultrasensitive malaria diagnosis in Burkina Faso. J. Infect. Dis. 213, 90–99 (2016).
5. Wu, L. et al. Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies. Nature 528, S86–S93 (2015).
6. Eisele, T. P. et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: A cluster-randomized controlled trial. J. Infect. Dis. 214, 1831–1839 (2016).
7. World Health Organization: The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria (WHO, Geneva, Switzerland) (2015).
8. von Seidlein, L. et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Med. 16(2), e1002745 (2019).
9. Morris, U. et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine. 16(1), 215 (2018).
10. Noor, A. M. et al. The risks of malaria infection in Kenya in 2009. BMC Infect. Dis. 9, 180, 10.1186/1471-2334-9-180 (2009).
11. Idris, Z. M. et al. High and heterogeneous prevalence of asymptomatic and sub-microscopic malaria infections on islands in Lake Victoria, Kenya. Sci. Rep. 6, 36958, 10.1038/srep36958 (2016).
12. World Health Organization: Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity (WHO, Geneva, Switzerland) (2011).
13. Kaneko, A. et al. Malaria eradication on islands. Lancet 356, 1560–1564 (2000).
14. Kaneko, A. A community-directed strategy for sustainable malaria elimination on islands: Short-term MDA integrated with ITNs and robust surveillance. Acta Trop. 114(3), 177–183 (2010).
15. Kaneko, A. et al. Characteristic age distribution of Plasmodium vivax infections after malaria elimination on Aneityum Island, Vanuatu. Infect. Immun. 82(1), 243–252 (2014).
16. Department of Health. The Executive Yuan Republic of China. Malaria eradication in Lanyu. Malaria Eradication in Taiwan (pp. 245–262 (1991).
17. World Health Organization Regional Office for the Western Pacific: Report of the Third Inter-Territorial Malaria Conference for the South-West Pacific. Honiara, Solomon Islands (1964).
18. Song, J. et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar. J. 9, 57, 10.1186/1475-2875-9-57 (2010).
19. Landier, J. et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet 391, 1916–1926 (2018).
20. Shekalaghe, S. A. et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malar. J. 10, 247, 10.1186/1475-2875-10-247 (2011).
21. von Seidlein, L. et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: A double-blind, community-randomized, placebo-controlled trial in the Gambia. Trans. R. Soc. Trop. Med. Hyg. 97, 217–225 (2003).
22. Deng, C. et al. Large-scale artemisinin–piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin. Infect. Dis. 67, 1670–1676 (2018).
23. Cook, J. et al. Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J. Infect. Dis. 211(9), 1476–1483 (2015).
24. Homann, M. V. et al. Detection of malaria parasites after treatment in travelers: A 12-months longitudinal study and statistical modelling analysis. EBioMedicine. 25, 66–72 (2017).
25. Jarra, W. & Snounou, G. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Infect. Immun. 66, 3783–3787 (1998).
26. Churcher, T. S. et al. Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. eLife. 2, e00626 (2013).
27. Nguyen, T.-N. et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet. 18, 5, 10.1016/S1473-3099(18)30046-X (2018).
28. Lwin, K. M. et al. Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malar. J. 14, 319, 10.1186/s12936-015-0838-5 (2015).
29. Tripura, R. et al. A controlled trial of mass drug administration to interrupt transmission of multi drug resistant falciparum malaria in Cambodian villages. Clin. Infect. Dis. 67, 817–826 (2018).
30. Das, S. et al. Performance of a high-sensitivity rapid diagnostic test for Plasmodium falciparum malaria in asymptomatic individuals from Uganda and Myanmar and naive human challenge infections. Am. J. Trop. Med. Hyg. 97(5), 1540–1550 (2017).
31. Hofmann, N. E. et al. Diagnostic performance of conventional and ultrasensitive rapid diagnostic tests for malaria in febrile outpatients in Tanzania. J. Infect. Dis. 219(9), 1490–1498 (2019).
32. Mytton, O. T. et al. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 77, 447–450 (2007).
33. Vanachayangkul, P. et al. Piperaquine population pharmacokinetics and cardiac safety in Cambodia. Antimicrob. Agents Chemother. 61, e02000–e02016 (2017).
34. Kachur, S. P. et al. Review of mass drug administration for malaria and its operational challenges. Am. J. Trop. Med. Hyg. 93, 125–134 (2015).
35. Cheah, P. Y. & White, N. J. Antimalarial mass drug administration: ethical considerations. Int. Health 8, 235–238 (2016).
36. Dial, N. J., Ceesay, S. J., Gosling, R. D., D’Alessandro, U. & Baltzell, K. A. A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar. J. 13, 47, 10.1186/1475-2875-13-47 (2014).
37. Landier, J. et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar. Wellcome open Res. 2, 81, 10.12688/wellcomeopenres.12240.1 (2017).
38. White, N. J. Does antimalarial mass drug administration increase or decrease the risk of resistance? Lancet Infect. Dis. 17, e15–e20 (2017).
39. Wernsdorfer, W. H. The biological and epidemiological basis of drug resistance in malaria parasites. Southeast Asian J. Trop. Med. Public Health 23(Suppl 4), 123–129 (1992).
40. von Seidlein, L. & Dondorp, A. Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance. Expert Rev. Anti. Infect. Ther. 13, 715–730 (2015).
41. White, N. J. et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar. J. 8, 253, 10.1186/1475-2875-8-253 (2009).
42. Graves, P. M., Gelband, H. & Garner, P. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane database Syst. Rev. 10.1002/14651858.CD008152.pub4 (2015).
43. White, N. J. et al. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 11, 418, 10.1186/1475-2875-11-418 (2012).
44. Crowell, V. et al. Can we depend on case management to prevent re-establishment of P. falciparum malaria, after local interruption of transmission? Epidemics 4, 1–8 (2012).
45. Gerardin, J. et al. Optimal population-level infection detection strategies for malaria control and elimination in a spatial model of malaria transmission. PLOS Comput. Biol. 12, e1004707 (2016).
46. Reiner, R. C. et al. Mapping residual transmission for malaria elimination. Elife 4, 10.7554/eLife.09520 (2015).
47. Iwashita, H. et al. Sleeping arrangement and house structure affect bed net use in villages along Lake Victoria. Malar. J. 9, 176, 10.1186/1475-2875-9-176 (2010).
48. Bhatt, S. et al. Coverage and system efficiencies of insecticide-treated nets in Africa from 2000 to 2017. Elife 4, 10.7554/eLife.09672.001 (2015).
49. Kirby, M. J. et al. Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. Lancet 374, 998–1009 (2009).
50. Tusting, L. S. et al. The evidence for improving housing to reduce malaria: a systematic review and meta-analysis. Malar. J. 14, 209, 10.1186/s12936-015-0724-1 (2015).
51. Futami, K. et al. Impacts of insecticide treated bed nets on Anopheles gambiae s.l. populations in Mbita district and Suba district, Western Kenya. Parasit. Vectors 7, 63, 10.1186/1756-3305-7-63 (2014).
52. Kawada, H. et al. Multimodal pyrethroid resistance in malaria vectors, Anopheles gambiae s.s., Anopheles arabiensis, and Anopheles funestus s.s. in Western Kenya. PLoS One 6, 10.1371/journal.pone.0022574 (2011).
53. Slater, H. C., Walker, P. G. T., Bousema, T., Okell, L. C. & Ghani, A. C. The potential impact of adding ivermectin to a mass treatment intervention to reduce malaria transmission: a modelling study. J. Infect. Dis. 210, 1972–1980 (2014).
54. Ouédraogo, A. L. et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin. Infect. Dis. 60, 357–365 (2015).
55. Idris, Z. M. et al. Naturally acquired antibody response to Plasmodium falciparum describes heterogeneity in transmission on islands in Lake Victoria. Sci. Rep. 7, 9123, 10.1038/s41598-017-09585-4 (2017).
56. Isozumi, R. et al. Improved detection of malaria cases in island settings of Vanuatu and Kenya by PCR that targets the Plasmodium mitochondrial cytochrome c oxidase III (cox3) gene. Parasitol. Int. 64, 304–308 (2015).